---
title: "BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296904391.md"
description: "Availability of the initial and sole oral preventive treatment for patients aged 2 to under 12 with hereditary angioedema (HAE) has now been extended in Japan. This development marks a significant increase in treatment options for younger individuals affected by HAE in the country."
datetime: "2026-08-25T11:03:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296904391.md)
  - [en](https://longbridge.com/en/news/296904391.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296904391.md)
generator: "portal-rs"
---

# BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

Availability of the initial and sole oral preventive treatment for patients aged 2 to under 12 with hereditary angioedema (HAE) has now been extended in Japan. This development marks a significant increase in treatment options for younger individuals affected by HAE in the country.

### Related Stocks

- [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md)

## Related News & Research

- [BioCryst says Japan approves Orladeyo for pediatric HAE patients aged 2-11](https://longbridge.com/en/news/296901994.md)
- [Applebee’s® and IHOP® Continue Nationwide Growth With New Dual-Branded Restaurant in San Antonio, TX | DIN Stock News](https://longbridge.com/en/news/299087521.md)
- [Pharvaris rises on late-stage trial win for hereditary angioedema drug](https://longbridge.com/en/news/298315480.md)
- [NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects](https://longbridge.com/en/news/298966653.md)
- [PHVS: Deucrictibant XR cut HAE attack rates by 83% in Phase 3, meeting all efficacy and safety endpoints](https://longbridge.com/en/news/298306223.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**